In patients with heart failure and reduced ejection fraction with and without T2DM, the DAPA-HF trial (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) demonstrated that the SGLT2 inhibitor reduces the risk of heart failure hospitalizations or CV death and slow the progression of kidney function decline (Jhund et al. 2021; Packer et al. 2020). This evidence concerns the gene SLC5A2 and heart failure.